The first study to compare molecular landscapes of early-onset and late-onset appendiceal cancer has revealed distinct non-silent mutations in the tumors of younger patients, setting the stage for the development of potential therapeutic advances for this rare disease.

The first study of appendiceal cancer patterns and survival by race/ethnicity among patients younger than 50 in the U.S. showed survival disparities.